default author photo

Liang Zeng

Central South University - Department of Medical Oncology

China

SCHOLARLY PAPERS

4

DOWNLOADS

212

TOTAL CITATIONS

5

Scholarly Papers (4)

1.

Antitumor Activity of First-Line Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancers: A Large Cohort, Multi-Center, Retrospective Study

Number of pages: 27 Posted: 28 Oct 2020
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Central South University - Department of Medical Oncology, Burning Rock Biotech, Burning Rock Biotech, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Tongji University School of Medicine - Department of Pathology, Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Genetics, School of Life Science, Anhui Medical University, Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Department of Radiotherapy; Qilu Hospital of Shandong University, Huazhong University of Science and Technology - Cancer Center, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, First Affiliated Hospital, China Medical University, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Chinese Academy of Sciences (CAS) - Department of Medical Oncology, University of California, Irvine - Chao Family Comprehensive Cancer Center and Central South University - Department of Medical Oncology
Downloads 72 (860,052)

Abstract:

Loading...

ROS1 fusion, ROS1 gene rearrangements, crizotinib, non-CD74 ROS1 fusions, crizotinib resistance mechanism

2.

Landscape of Next Generation Sequencing in Screening Accurate Benefit Population for First Line Crizotinib in ALK Rearranged Advanced Non-Small Cell Lung Cancer

Number of pages: 21 Posted: 24 Jan 2019
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Second Chest Cancer Unit, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 56 (1,000,027)
Citation 4

Abstract:

Loading...

NGS, Ventana, ALK, Fusion partners, Crizotinib

3.

Apatinib Plus Vinorelbine in Second Line Treatment Failure Wildtype Advanced Non-Small Cell Lung Cancer (VICTOR): A Phase II Three-Dimensional Co-Culture Platforms-Guided Prospective Study

Number of pages: 33 Posted: 24 Sep 2019
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Hepatology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, The University of Texas MD Anderson Cancer Center - Department of Experimental Radiation Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 46 (1,109,210)
Citation 1

Abstract:

Loading...

Three-Dimensional Co-Culture, Apatinib, Vinorelbine, Second Line Treatment Failure, Non-small Cell Lung Cancer, Prospective Study

4.

Apatinib Combined with Vinorelbine in Second Line Treatment Failure Non-Driver Mutation Advanced Non-Small Cell Lung Cancer(VICTOR): A Phase 2, Single-Arm, Prospective Study

Number of pages: 24 Posted: 22 May 2019
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Hepatology, Central South University - Department of Medical Oncology, Central South University - Department of Pharmacy, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, The University of Texas MD Anderson Cancer Center - Department of Experimental Radiation Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 38 (1,209,354)

Abstract:

Loading...

Apatinib, Vinorelbine, Second Line Treatment Failure, Non-small Cell Lung Cancer, Prospective Study